Priovant Therapeutics - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomePriovant Therapeutics
Priovant Therapeutics logo

Priovant Therapeutics

0 followers

About Priovant Therapeutics

Priovant Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for patients with severe autoimmune diseases. The company operates in the biotechnology and biopharmaceutical sectors, pursuing research and clinical development to bring therapeutic options to patients with autoimmune conditions. The site presents Priovant as a U.S.-based organization dedicated to advancing treatments for autoimmune diseases.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Paul Mudd

Chief Development Officer

Frank Torti

Executive Chairman

Daniel Herz-Roiphe

Chief Operating Officer

Ben Zimmer

Chief Executive Officer

Katharina Shaw

VP, Medical Affairs & Head of Dermatology Strategy

Key Facts

HQ Location

Durham, United States

Employees

51 - 200

Status

Private

Website

https://priovant.com